{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:54Z","timestamp":1791489654808,"version":"4.3.4"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Iron deficiency is the leading cause of anemia, which affects 1 quarter of the adult population globally. Intravenous iron is a well-established treatment option and is generally well tolerated. However, there is increasing recognition that it can cause hypophosphatemia, which can result in fatigue, nausea, myalgia, weakness, and osteomalacia. We sought to determine the prevalence, natural history, and predictors of hypophosphatemia following iron infusion in a tertiary hospital. All adult patients who received 1 or more iron infusions between January 1, 2019 and December 31, 2021 were included in this retrospective study. A total of 2367 subjects were identified, receiving a total of 7063 infusions over the study period. Hypophosphatemia was defined as a serum phosphate level of &amp;lt;0.75\u00a0mmol\/L (&amp;lt;2.32\u00a0mg\/dL), with severity classified as mild 0.65-0.75\u00a0mmol\/L (2.01-2.31\u00a0mg\/dL), moderate 0.32-0.64\u00a0mmol\/L (0.99-1.98\u00a0mg\/dL), or severe &amp;lt;0.32\u00a0mmol\/L (&amp;lt;0.99\u00a0mg\/dL). Prevalence of hypophosphatemia was 48.9%, with the highest prevalence from day 4 to 20 post-iron infusion (39.3%-44.1%). Risk factors were receipt of iron polymaltose (odds ratio [OR] 2.33, CI 1.71-3.19, p\u00a0&amp;lt;\u2009.0001), receipt of ferric carboxymaltose (OR 1.79, CI 1.29-2.48, p\u00a0=\u2009.001), male gender (OR 1.35, CI 1.09-1.66, p\u00a0=\u2009.006), and multiple iron infusions (OR 1.56, CI 1.20-2.03, p\u00a0=\u2009.001). Risk was reduced in recipients with higher baseline phosphate (OR 0.18, CI 0.11-0.28, p\u00a0&amp;lt;\u2009.0001), higher baseline creatinine (OR 0.83, CI 0.74-0.92, p\u00a0=\u2009.001), and increased weight (OR 0.99, CI 0.99-1.00, p\u00a0=\u2009.016). Risk factors for moderate to severe hypophosphatemia were the same, except that gender became nonsignificant, while increasing age (OR 0.99, CI 0.99-1.00, p\u00a0=\u2009.002) was also associated with reduced risk. These findings may aid clinicians in identifying those at greatest risk of developing significant hypophosphatemia, thereby preventing adverse outcomes.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf014","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:15:52Z","timestamp":1737357352000},"page":"v69-v78","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence, predictors, and natural history of hypophosphatemia following iron infusion"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-0971","authenticated-orcid":false,"given":"Chloe","family":"Dawson","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Alfred Health , Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"School of Public Health and Preventive Medicine, Monash University , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Ming Kathleen","family":"Pak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Alfred Health , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldho","family":"Paul","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Szwarcbard","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Alfred Health , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Hackman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Alfred Health , Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Medicine, Monash University , Melbourne, VIC 3800 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"2025122308364445900_ref1","article-title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990\u20132021: findings from the global burden of disease study 2021","volume":"10","author":"GBD Anaemia Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"key":"2025122308364445900_ref2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2326-11-4","article-title":"Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data","volume":"11","author":"Moore","year":"2011","journal-title":"BMC Blood Disord"},{"key":"2025122308364445900_ref3","volume-title":"Australian Product Information\u2014Ferrosig (Iron Polymaltose)","author":"Therapeutic Goods Administration","year":"2022"},{"key":"2025122308364445900_ref4","volume-title":"Australian Product Information\u2014Ferinject (Ferric Carboxymaltose) Solution for Injection","author":"Therapeutic Goods Administration","year":"2018"},{"key":"2025122308364445900_ref5","volume-title":"Australia Product Information\u2014Venofer (Iron Sucrose)","author":"Therapeutic Goods Administration","year":"2024"},{"key":"2025122308364445900_ref6","volume-title":"Australian Product Information\u2014Monofer (Ferric Derisomaltose)","author":"Therapeutic Goods Administration","year":"2024"},{"key":"2025122308364445900_ref7","volume-title":"Iron Product Choice and Dose Calculation for Adults","author":"National Blood Authority","year":"2016"},{"key":"2025122308364445900_ref8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/jppr.1158","article-title":"Safety of rapid infusion of iron polymaltose: comparative study in 300 patients","volume":"46","author":"Chan","year":"2016","journal-title":"J Pharm Pract Res"},{"key":"2025122308364445900_ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy","year":"2015","journal-title":"Int J Rheumatol"},{"key":"2025122308364445900_ref10","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0065","article-title":"Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction","volume":"2019","author":"Ifie","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2025122308364445900_ref11","doi-asserted-by":"publisher","first-page":"001860","DOI":"10.12890\/2020_001860","article-title":"Severe symptomatic hypophosphataemia as a complication of parenteral iron replacement","volume":"7","author":"Teh","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"key":"2025122308364445900_ref12","first-page":"49","article-title":"Severe hypophosphataemia after intravenous iron administration","volume":"72","author":"Blazevic","year":"2014","journal-title":"Neth J Med"},{"key":"2025122308364445900_ref13","doi-asserted-by":"publisher","first-page":"bcr2016219160","DOI":"10.1136\/bcr-2016-219160","article-title":"Severe hypophosphataemia after intravenous iron administration","volume":"2017","author":"Anand","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2025122308364445900_ref14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jbmr.3319","article-title":"Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report","volume":"33","author":"Bartko","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2025122308364445900_ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-222851","article-title":"Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration","volume":"2018","author":"Klein","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2025122308364445900_ref16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4045\/tidsskr.12.0494","article-title":"Uncommon adverse effect of a common medication","volume":"133","author":"Moore","year":"2013","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2025122308364445900_ref17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/jbmr.3369","article-title":"Iron supplementation-induced phosphaturic osteomalacia: FGF23 is the culprit","volume":"33","author":"Urbina","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2025122308364445900_ref18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1681\/ASN.2007020143","article-title":"Hypophosphatemia: clinical consequences and management","volume":"18","author":"Brunelli","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025122308364445900_ref19","first-page":"381","article-title":"Hypophosphatemia induced encephalopathy after intravenous iron carboxymaltase administration\u2014a rare and important complication","volume":"24","author":"U","year":"2019","journal-title":"Neurol Asia"},{"key":"2025122308364445900_ref20","first-page":"521","article-title":"Hypophosphatemia after treatment with parenteral iron: case report","volume":"90","author":"Mihela\u010d","year":"2021","journal-title":"Slov Med J"},{"key":"2025122308364445900_ref21","first-page":"250","article-title":"Life threatening rapid onset of hypophosphatemia developed due to intravenous iron replacement following pulmonary resection; a case report","volume":"26","author":"Erdo\u011fdu","year":"2020","journal-title":"GKDA Derg"},{"key":"2025122308364445900_ref22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.nefroe.2021.08.006","article-title":"Life-threatening hypophosphatemia following intravenous iron infusion","volume":"41","author":"Vasquez-Rios","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"key":"2025122308364445900_ref23","doi-asserted-by":"publisher","first-page":"p329","DOI":"10.1530\/endoabs.94.P329","article-title":"Persistent hypophosphatemia and recurrent seizures after ferric carboxymaltose (FCM)","volume":"94","author":"Subbiah","year":"2023","journal-title":"Endocr Abstr"},{"key":"2025122308364445900_ref24","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2025122308364445900_ref25","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works","volume":"18","author":"Liu","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025122308364445900_ref26","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1530\/JME-20-0178","article-title":"FGF23 signalling and physiology","volume":"66","author":"Ho","year":"2021","journal-title":"J Mol Endocrinol"},{"key":"2025122308364445900_ref27","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol Asp Med"},{"key":"2025122308364445900_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"2025122308364445900_ref29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"2025122308364445900_ref30","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025122308364445900_ref31","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2025122308364445900_ref32","doi-asserted-by":"publisher","first-page":"e0167146","DOI":"10.1371\/journal.pone.0167146","article-title":"Choice of high-dose intravenous iron preparation determines hypophosphatemia risk","volume":"11","author":"Schaefer","year":"2016","journal-title":"PLoS One"},{"key":"2025122308364445900_ref33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"2025122308364445900_ref34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron Isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"2025122308364445900_ref35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","article-title":"Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose","volume":"107","author":"Schaefer","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2025122308364445900_ref36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12937-024-00982-w","article-title":"The association between serum phosphate and length of hospital stay and all-cause mortality in adult patients: a cross-sectional study","volume":"23","author":"Zhou","year":"2024","journal-title":"Nutr J"},{"key":"2025122308364445900_ref37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/000456329903600104","article-title":"Hypophosphataemia in general practice patients","volume":"36","author":"Guy","year":"1999","journal-title":"Ann Clin Biochem"},{"key":"2025122308364445900_ref38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12185-018-2529-9","article-title":"Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study","volume":"109","author":"Ikuta","year":"2019","journal-title":"Int J Hematol"},{"key":"2025122308364445900_ref39","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev","year":"2011","journal-title":"Gastroenterology"},{"key":"2025122308364445900_ref40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12916-020-01643-5","article-title":"Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study","volume":"18","author":"Emrich","year":"2020","journal-title":"BMC Med"},{"key":"2025122308364445900_ref41","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","article-title":"A randomized, open-label trial of iron isomaltoside 1000 (Monofer(R)) compared with iron sucrose (Venofer(R)) as maintenance therapy in haemodialysis patients","volume":"30","author":"Bhandari","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025122308364445900_ref42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"key":"2025122308364445900_ref43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drudis.2019.09.020","article-title":"Iron oxide nanoparticles for therapeutic applications","volume":"25","author":"Alphand\u00e9ry","year":"2020","journal-title":"Drug Discov Today"},{"key":"2025122308364445900_ref44","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.3390\/ijms23042140","article-title":"Criticality of surface characteristics of intravenous iron-carbohydrate nanoparticle complexes: implications for pharmacokinetics and pharmacodynamics","volume":"23","author":"Funk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025122308364445900_ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/172104","article-title":"Safety and efficacy of intravenous ferric carboxymaltose (750\u00a0mg) in the treatment of iron deficiency anemia: two randomized, controlled trials","volume":"2012","author":"Barish","year":"2012","journal-title":"Anemia"},{"key":"2025122308364445900_ref46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"2025122308364445900_ref47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/clinchem\/32.1.76","article-title":"Reference intervals for calcium, phosphate, and alkaline phosphatase as derived on the basis of multichannel-analyzer profiles","volume":"32","author":"Sinton","year":"1986","journal-title":"Clin Chem"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf014\/61529659\/ziaf014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/Supplement_5\/v69\/61529659\/ziaf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/Supplement_5\/v69\/61529659\/ziaf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:36:50Z","timestamp":1766497010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/9\/Supplement_5\/v69\/7965786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"journal-issue":{"issue":"Supplement_5","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf014","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12]]}}}